Jim Cramer Says "CRISPR Can Either Triple or Do Nothing"

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the stocks that Jim Cramer weighed in on. When a caller inquired about the company, Cramer stated:

“You see, here’s the deal: There’s so many stocks that are going up. People don’t even like think, it’s like, oh man, boy, I forgot about CRISPR. Well, I haven’t. I think CRISPR is a terrific, terrific, but speculative situation, and I think you should be able to speculate. I think CRISPR, look, CRISPR can either triple or do nothing. That’s not a bad ratio.”

CRISPR (NASDAQ:CRSP) develops gene-based medicines using its CRISPR/Cas9 platform, which targets a range of diseases, including hemoglobinopathies, cancer, cardiovascular conditions, and type 1 diabetes. The company’s lead therapy is focused on gene-edited treatment for sickle cell disease and beta-thalassemia. Cramer mentioned the company in a January episode and said:

“You know, I want to own, I want to own CRISPR because I keep seeing their name come up and all the science papers that I read and I read quite a bit of them, but boy, the stock’s been a tough own. Let’s put some away and then if it goes lower, we’ll buy more. But I, I understand. How could that company keep losing money like this? It is just, it’s Moderna-like… in the money they throw in the chimney.”

While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.